Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair

Signs Ten Letters of Intent With New Distributors

HARBIN, China, July 2 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company successfully exhibited its Siberian Ginseng (Acanthopanax)-based products at the 21st China Harbin International Economic and Trade Fair ("Harbin Trade Fair") from June 15 to June 19, 2010.

The Harbin Trade Fair is one of the large-scale foreign trade fairs authorized by the Chinese government. Over the years, Harbin Trade Fair has developed from a regional fair to a large-scale international economic and trade fair with 3,000 international standard booths and 10 professional exhibition areas. Harbin Trade Fair has become one of the most significant international trade fairs in the world -- a window for China to fully explore the diversified international market and a major platform for regional cooperation in Northeast Asia. Renhuang's booth showcased the Company's wide range of Siberian Ginseng-based medications and was visited by thousands of interested attendees. Siberian Ginseng has well-documented health benefits for treating depression and anxiety without the side effects often associated with chemical-based drugs.

The Company signed ten new letters of intent with distributors at the Harbin Trade Fair, which the Company estimates will contribute approximately RMB3.0 million (approximately $0.4 million) to its fiscal year 2010 revenue.

"Our participation at the Harbin Trade Fair was of great significance for enhancing our corporate image and increasing our brand influence," said Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "Harbin Trade Fair provides a key trade discussion platform for domestic and international enterprises. We are delighted that our Siberian Ginseng-based products command positive market recognition and growing acceptance in the industry, and we look forward to participating in similar trade shows to enhance our visibility and build industry and customer relationships."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's participation in the 21st China Harbin International Economic and Trade Fair and expected positive outcomes, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

For more information, please contact:

Renhuang Pharmaceuticals, Inc.

Ms. Portia Tan, IR Contact

Phone: +86-451-8260-2162

Email: ir@renhuang.com

CCG Investor Relations:

Mr. Mark Collinson, Partner

Phone: +1-310-954-1343 (Los Angeles)

Email: mark.collinson@ccgir.com

Web: http://www.ccgirasia.com

Mr. Crocker Coulson, President

Phone: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com